Edap Tms (NASDAQ:EDAP) Rating Lowered to Hold at Zacks Investment Research

Edap Tms (NASDAQ:EDAP) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Tuesday, Zacks.com reports.

According to Zacks, “EDAP TMS S.A. develops, produces, markets and distributes minimally invasive medical devices, primarily for the treatment of urological diseases. They currently produce and market devices for treatment of benign prostate hyperplasia and urinary tract stones. They are also developing a third range of products for minimally invasive destruction of certain types of tumors. “

EDAP has been the subject of a number of other research reports. HC Wainwright reissued a “buy” rating and set a $6.50 target price on shares of Edap Tms in a research report on Friday. ValuEngine lowered shares of Edap Tms from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd.

Edap Tms stock traded down $0.08 on Tuesday, reaching $4.86. 180,600 shares of the stock were exchanged, compared to its average volume of 183,308. The stock has a market cap of $140.35 million, a PE ratio of 243.00 and a beta of 1.84. Edap Tms has a twelve month low of $1.35 and a twelve month high of $5.42. The firm has a fifty day moving average price of $4.68 and a two-hundred day moving average price of $3.65.

Edap Tms (NASDAQ:EDAP) last released its earnings results on Wednesday, November 13th. The medical equipment provider reported $0.03 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.04 by ($0.01). The firm had revenue of $11.35 million for the quarter, compared to analyst estimates of $13.15 million. Edap Tms had a return on equity of 40.29% and a net margin of 7.61%. Equities analysts anticipate that Edap Tms will post 0.18 EPS for the current fiscal year.

Institutional investors and hedge funds have recently made changes to their positions in the company. Russell Investments Group Ltd. raised its position in shares of Edap Tms by 168.4% during the third quarter. Russell Investments Group Ltd. now owns 7,332 shares of the medical equipment provider’s stock valued at $33,000 after buying an additional 4,600 shares during the last quarter. Commonwealth Equity Services LLC raised its position in shares of Edap Tms by 25.0% during the third quarter. Commonwealth Equity Services LLC now owns 32,540 shares of the medical equipment provider’s stock valued at $146,000 after buying an additional 6,500 shares during the last quarter. JPMorgan Chase & Co. acquired a new position in shares of Edap Tms during the second quarter valued at about $282,000. Susquehanna International Group LLP raised its position in shares of Edap Tms by 762.9% during the second quarter. Susquehanna International Group LLP now owns 205,178 shares of the medical equipment provider’s stock valued at $556,000 after buying an additional 181,401 shares during the last quarter. Finally, Acadian Asset Management LLC acquired a new position in shares of Edap Tms during the second quarter valued at about $607,000. 12.54% of the stock is owned by institutional investors and hedge funds.

Edap Tms Company Profile

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally-invasive medical devices for the treatment of urological diseases worldwide. The company operates in two divisions: High Intensity Focused Ultrasound (HIFU), and Urology Devices and Services (UDS).

Featured Article: What Are Treasury Bonds?

Get a free copy of the Zacks research report on Edap Tms (EDAP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Edap Tms Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edap Tms and related companies with MarketBeat.com's FREE daily email newsletter.